HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Article

Ann Thorac Surg 2000;70:871-872
© 2000 The Society of Thoracic Surgeons

---

Discussion

Discussion

Discussion

DR AXEL HAVERICH (Hannover, Germany): From your experience with this study and from data probably available from other GP IIb/IIIa inhibitors, do you know if there is a difference between Reopro and your compound in terms of bleeding complications after bypass surgery?

DR BHATIA: Thank you Dr Haverich. Conflicting reports have been published, however, there has not been a large study that has looked at patients that have received either Reopro or other short-acting IIb/IIIa inhibitors and undergone immediate surgery. At our institution, we reviewed 23 consecutive patients that went to surgery emergently after receiving Reopro and the transfusion requirements were considerably higher in the group of patients who went to surgery within 24 hours of administration, compared with patients in whom surgery was delayed.

DR HAVERICH: That would mimic our experience in Germany.

DR EDMUND NAGEM (Lafayette, LA): Doctor Bhatia, do you think that similarity between the placebo . . . [Full Text of this Article]

Related Article

Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT

Cornelius M. Dyke, Devinder Bhatia, Todd J. Lorenz, Steven P. Marso, Barbara E. Tardiff, Charissa Hogeboom, and Robert A. Harrington
Ann. Thorac. Surg. 2000 70: 866-871. [Abstract] [Full Text] [PDF]